Upfront therapy with allogeneic hematopoietic stem cell transplantation versus DNA methyltransferase inhibitors in patients with vexas syndrome: A comparative matched cohort efficacy analysis of 39 patients

Saubia Fathima(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Mithun Vinod Shah(Mayo Clinic in Arizona), Horatiu Olteanu(Mayo Clinic in Arizona), Urshila Durani(Mayo Clinic), Saurabh Chhabra(Medical College of Wisconsin), Ronald S. Go(Mayo Clinic), Mary Riwes(University of Michigan), Terra Lasho(Mayo Clinic), Ali Alsugair(Mayo Clinic in Arizona), Aasiya Matin(Mayo Clinic in Arizona), Jade L. Kutzke(Mayo Clinic), Kenneth J. Warrington(Mayo Clinic), Joseph P. McGuirk(University of Kansas Medical Center), Amelia Langston(CancerCare Manitoba), Jeanne Palmer(Mayo Clinic), Hassan B. Alkhateeb(Mayo Clinic), Yael Kusne(WinnMed), Mehrdad Hefazi(Mayo Clinic), Elizabeth F. Krakow(Fred Hutch Cancer Center), Mrinal M. Patnaik(Mayo Clinic), Gabriel Bartoo(Mayo Clinic), Taxiarchis Kourelis(Mayo Clinic in Arizona), Kristen McCullough(Mayo Clinic), Christy M. Finke(Mayo Clinic), William J. Hogan(Mayo Clinic), Kaaren K. Reichard(Mayo Clinic), Mark R. Litzow(Mayo Clinic in Arizona), David Dingli, Kimberly J. Langer(Mayo Clinic), Matthew J. Koster(Mayo Clinic in Arizona)
Blood
November 3, 2025
Cited by 0


Related Papers